Newswires
Validation of the French Versions of the PHQ-4 Anxiety and Depression Scale and the PC-PTSD-5 Post-Traumatic Stress Disorder Screening Scale: Mental Health Diseases and Conditions – Anxiety Disorders
2026 FEB 20 (NewsRx) -- By a
As a matter of record, on
Tracking Information
| Trial Identifier | NCT07396623 |
| First Submitted Date | |
| First Posted Date | |
| Results First Submitted Date | Not Provided |
| Results First Posted Date | Not Provided |
| Last Update Submitted Date | |
| Last Update Posted Date | |
| Primary Completion Date | |
| Start Date | 2026-01-26 |
| Current Primary Outcome Measures | •Assess the validity of the French version of the PHQ-4 (Patient Health Questionnaire-4 ) scale [ Time Frame: 14 days ] -- This scale is used for the screening of anxiety and depression. The scale will be scored. Score ranging from 0 to 12, corresponding to four levels of psychological distress: * None: 0-2 * Mild: 3-5 * Moderate: 6-8 * Severe: 9-12 Patients will complete this scale at Visit 1 and Visit 2. |
| •Assess the validity of the French version of the PC-TDSD-5 (Primary Care PTSD Screen for DSM-5) scale [ Time Frame: 14 days ] -- Scale assessing whether the patient has experienced unusually or particularly frightening, horrible, or traumatic events. Examples include: * A serious accident or fire * Physical or sexual assault, or sexual abuse * An earthquake or flood * War * Witnessing a person being killed or seriously injured * The death of a close person by homicide or suicide Total score = sum of “YES” responses to questions 1 through 5. Patients will complete this scale at Visit 1 and Visit 2. | |
| Current Secondary Outcome Measures | •Assess the feasibility of this screening tool during the first evaluation visit. [ Time Frame: At Visit 1 (at inclusion) ] -- The time required for the patient to complete each scale (individually) will be timed and recorded (without informing the patient in order to avoid potential stress). |
| Other Outcome Measures | Not Provided |
| Change History | Complete list of historical revisions of study NCT07396623 |
Descriptive Information
| Brief Title | Validation of French PHQ-4 and PC-PTSD-5 Screening Scales |
| Official Title | Validation of the French Versions of the PHQ-4 Anxiety and Depression Scale and the PC-PTSD-5 Post-Traumatic Stress Disorder Screening Scale |
| Brief Summary | Mental illness is a major public health issue. It affects one in five people, represents the largest expense for health insurance (14%), is the leading cause of years lived with disability, and suicide is the main cause of death among people aged 15 to 35. Depression affects 15 to 20% of individuals at some point in their lives. Trauma-related disorders affect 4.6% of people, including 1- 2% with post-traumatic stress disorder (PTSD). Screening for mental health problems in primary care is crucial. It enables doctors to provide early treatment, reduces the need for emergency care, and decreases both the number and duration of hospital stays. However, general practitioners and other non-mental health professionals often report lacking the time, training, and tools to conduct such screenings. Fortunately, brief and validated screening tools exist in English: The PHQ-4 (Patient Health Questionnaire-4) for anxiety and depression, and the PC-PTSD-5 (Primary Care PTSD Screen for DSM-5) for PTSD. So far, no French versions of these tools have been validated. |
| Detailed Description | A target of 10 patients per item of the tested scales was set. The PHQ-4 includes four items and the PC-PTSD-5 includes five items, corresponding to required sample sizes of 40 and 50 patients, respectively. Although the same patient sample completes both scales, these sample sizes were combined to account for potential loss to follow-up and to optimize statistical power, resulting in a total inclusion target of 90 patients. Descriptive analyses of sociodemographic and clinical characteristics will be conducted for all included patients. Quantitative variables will be summarized using means and standard deviations, and qualitative variables using frequencies and percentages. To address the primary objective, convergent validity will be assessed using Pearson’s correlation coefficients between scores obtained on the tested scales (PHQ-4 and PC-PTSD-5) and those obtained on their respective gold standard instruments (PHQ-9, GAD-7, and PCL-5). Convergent validity will also be examined by inclusion center through comparison of correlation coefficients across centers. Secondary objectives will be addressed through: * Exploratory factor analysis to examine the dimensional structure of each scale and to compare it with that of the corresponding gold standard. * Assessment of internal consistency using Cronbach’s alpha coefficient. Test-retest reliability will be evaluated using the intraclass correlation coefficient on a subsample of at least 20 participants, depending on the final total sample size, who will complete the PHQ-4 and PC-PTSD-5 scales twice. * Evaluation of diagnostic performance by calculating sensitivity and specificity for each scale among patients undergoing a psychiatric diagnostic assessment, with receiver operating characteristic (ROC) curves generated for each scale. * Assessment of feasibility based on the time required to complete both scales. All statistical tests will be two-sided and considered statistically significant at an alpha level of 0.05. No statistical imputation methods will be used for the management of missing data. |
| Study Type | OBSERVATIONAL |
| Study Phase | Not Provided |
| Study Design | Observational Model: COHORT |
| Time Perspective: PROSPECTIVE | |
| Target Follow-Up Duration | 554 Days |
| Condition | Mental Illness |
| Intervention | Not Provided |
| Study Arms | Not Provided |
Recruitment Information
| Recruitment Status | RECRUITING |
| Enrollment | 90 |
| Completion Date | 2027-08-15 |
| Primary Completion Date | |
| Eligibility | Inclusion Criteria: * Age ≥ 18 years, * Outpatient or hospitalized for any health-related reason, * Oral and written proficiency in French, * Patient informed and willing to participate in the study, * Patient with health insurance coverage Exclusion Criteria: * Individuals under legal protection measures (guardianship, conservatorship, or legal supervision), * Other factors preventing obtaining non-opposition or conducting the research, such as: limited French proficiency, hearing impairment, or significant cognitive disorders |
| Sex/Gender | Sexes Eligible for Study: ALL |
| Ages | 18 years to |
| f | |
| Contacts | Primary contact: Vladimir ADRIEN, Doctor, (+33) 1 48 95 59 37, [email protected] |
| Listed Location Countries | |
| Removed Location Countries |
Administrative Information
| NCT Number | NCT07396623 |
| Other Study ID Numbers | APHP250750 |
| Has Data Monitoring Committee | Not Provided |
| Not Provided | |
| Plan to Share Data (IPD) Description | Not Provided |
| Collaborators | Not Provided |
| Investigators | Not Provided |
| Information Provided By | Assistance Publique - Hopitaux de |
| Verification Date | 2026-01 |
(Our reports deliver fact-based news of research and discoveries from around the world.)
EmblemHealth will pay $2.5M after investigation reveals 'ghost network' of providers
Studies from Isfahan University of Medical Sciences in the Area of Risk Management Described (Evaluation and modeling of environmental stressors affecting enteric microbial survival in soil: Implications for wastewater reuse and risk management): Risk Management
Advisor News
- Addressing the ‘menopause tax:’ A guide for advisors with female clients
- Alternative investments in 401(k)s: What advisors must know
- The modern advisor: Merging income, insurance, and investments
- Financial shocks, caregiving gaps and inflation pressures persist
- Americans unprepared for increased longevity
More Advisor NewsAnnuity News
- Globe Life Inc. (NYSE: GL) Making Surprising Moves in Monday Session
- Aspida Life and WealthVest Offer a Powerful New Guaranteed Income Product with the WealthLock® Income Builder
- Lack of digital tools drives wedge between insurers, advisors
- LIMRA: Annuity sales notch 10th consecutive $100B+ quarter
- AIG to sell remaining shares in Corebridge Financial
More Annuity NewsHealth/Employee Benefits News
- Kansas state employees retain choice of Blue Cross, Aetna for health insurance
- Rob Sand unveils water quality, public health plan
- Mark Farrah Associates Assessed Year-End Health Insurance Segment Membership Trends
- Symetra Names Jeff Sealey Vice President, Stop Loss Captives
- Novus Capitalizes on Cannabis Rescheduling, Releases Q1 2026 Growth
More Health/Employee Benefits NewsLife Insurance News
- Symetra Names Jeff Sealey Vice President, Stop Loss Captives
- 3 ways AI can help close the gap for women’s insurance coverage
- Best’s Market Segment Report: AM Best Revises Outlook on Italy’s Life Insurance Segment to Stable From Negative
- Globe Life Inc. (NYSE: GL) Making Surprising Moves in Monday Session
- Dan Scholz to receive NAIFA’s Terry Headley Lifetime Defender Award
More Life Insurance News